Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
CYCLOCORT is a topical cream formulation containing a small-molecule corticosteroid approved in 1979 for dermatological inflammatory conditions. The active ingredient works through glucocorticoid receptor binding to reduce inflammation, pruritus, and immune-mediated skin responses. It is indicated for use in patients with steroid-responsive dermatoses.
As a product approaching loss of exclusivity in a mature dermatology market with moderate competitive pressure, the brand team is likely focused on cost management and line extensions rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
CYCLOCORT offers limited career growth opportunities given its mature status and approaching loss of exclusivity. Roles on this product focus primarily on managing decline, optimizing manufacturing costs, and protecting market share against generics rather than innovation or launch activities.
Worked on CYCLOCORT at Astellas? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.